DUBLIN--(BUSINESS WIRE)--The "Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
Global Non-Hodgkin Lymphoma Therapeutics market is expected witness a CAGR of 7.4% during the forecast period.
Certain factors that are driving the market growth include rise in prevalence of NHL, demand for innovative drugs and novel technologies, and increase in number of FDA approval for NHL therapy drugs.
In addition, increase in public awareness about NHL, robust drug pipeline for the treatment of the disease, improved diagnostic techniques to detect NHL, and increase in the prevalence of non-Hodgkin lymphoma are factors fuelling the NHL therapeutics market across the globe.
However, high cost of NHL drugs and various complications associated with them are acting as a major restraint for the non-Hodgkin lymphoma therapeutics market. Additionally, increasing rituximab resistance and stringent regulatory guidelines are also limiting the growth of the market.
Key Market Trends
Radiation Therapy is Expected to Hold Significant Market Share in the Type of Therapy
Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and may be delivered from a source outside the body, i.e. external beam radiation or internally such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks.
Radiation therapy is most effective when this kind of lymphoma is only found in one part of the body. For non-Hodgkin disease, radiation therapy is used in the early stages of the diseases. In case of advanced lymphomas, radiation therapy is used along with the chemotherapy for better results. If the lymphoma is wide spread, palliative radiotherapy is very helpful. Radiotherapy is often very good at destroying non-Hodgkin disease cells. It mainly helps in relieving from the symptoms caused by the lymphomas.
Asia-Pacific is Expected to Show Highest Growth Rate in the Forecast Period
The non-Hodgkin lymphoma therapeutics market is segmented by type of treatment and geography. By geography the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. North America dominates the non-Hodgkin lymphoma therapeutics market due to increasing technological advancements and the rising incidences of NHL in the country.
Asia-Pacific is also expected to propel the non-Hodgkin lymphoma therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region and increasing prevalence of NHL. According to the research article published in 2018, it was estimated that the incidence rate of non-Hodgkin lymphoma was 7.11 per 100 000 per year in China. As the incidence and prevalence of non-Hodgkin lymphoma are increasing year on year many manufacturing companies are investing to develop novel drug therapies to meet the growing demand of therapeutics.
Moreover, according to the research article published in 2015, Cancer Prevention Research in China, it was observed that the Chinese government has sponsored several large- and small-scale screening programs for the early detection of different cancers. Hence, with the growing awareness of the disease, increasing government initiatives, and increase in the prevalence and incidence of disease, the market is expected to grow over the forecast period.
The global Non-Hodgkin Lymphoma Therapeutics market is highly competitive and consists of a few major players. Companies like Accredo Health Group, AstraZeneca, Baxter International, Bayer, Celgene Corp, Cephalon, Eli Lilly and Co, F. Hoffmann La-Roche, GlaxoSmithKline, Spectrum Pharmaceuticals, among others, hold the substantial market share in the Non-Hodgkin Lymphoma Therapeutics market.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of NHL
4.2.2 Demand for Innovative Drugs & Novel Technologies
4.2.3 Increase in Number of FDA Approval for NHL Therapy Drugs
4.3 Market Restraints
4.3.1 High Cost of the Drugs Used in NHL Therapy
4.3.2 Side-Effects Associated with NHL Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type of Therapy
5.1.2 Radiation Therapy
5.1.3 Targeted Therapy
5.2 Cell Type
5.2.1 B-Cell Lymphomas
5.2.2 T-Cell Lymphoma
5.3.1 North America
188.8.131.52 Rest of Europe
5.3.3 Asia Pacific
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Accredo Health Group Inc.
6.1.3 Baxter International Inc.
6.1.4 Bayer AG
6.1.5 Celgene Corp.
6.1.6 Eli Lilly and Co.
6.1.7 F. Hoffmann La-Roche Ltd.
6.1.8 GlaxoSmithKline PLC
6.1.9 Spectrum Pharmaceuticals
6.1.10 Teva Pharmaceuticals
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/4iqdhj